A novel nano-formulation of olmesartan medoxomil with improved delivery and efficacy in the treatment of indomethacin-induced duodenitis in rats

A novel nano-formulation of olmesartan medoxomil with improved delivery and efficacy in the treatment of indomethacin-induced duodenitis in rats

There are few studies addressing duodenal inflammation. This study was designed to investigate the effects of a recently developed biotechnological product, a nano-formulation of olmesartan medoxomil (OM) - olmesartan medoxomil zeinmersomes (OMZ) - for the treatment of indomethacin-induced duodeniti...

Full description

Bibliographic Details
Main Authors:	H.A. Murad, T.M. Alqurashi
Format:	Article
Language:	English
Published:	Associação Brasileira de Divulgação Científica 2023-05-01
Series:	Brazilian Journal of Medical and Biological Research
Subjects:	Indomethacin Zeinmersomes Olmesartan medoxomil Duodenitis, Survivin
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2023000100636&lng=en&tlng=en

Similar Items

Stability-indicating comparative methods using mekc and lc for determination of olmesartan medoxomil
by: Lisiane Bajerski, et al.
Published: (2013-01-01)

Stability-indicating comparative methods using mekc and lc for determination of olmesartan medoxomil
by: Lisiane Bajerski, et al.
Published: (2013-01-01)

EVALUATION OF ANTIHYPERTENSIVE THERAPY WITH THE COMBINATION OF OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
by: Steven G. Chrysant, et al.
Published: (2011-06-01)

Olmesartan medoxomil self-microemulsifying drug delivery system reverses apoptosis and improves cell adhesion in trinitrobenzene sulfonic acid-induced colitis in rats
by: Hussam Murad, et al.
Published: (2022-12-01)

EFFECT OF ANGIOTENSIN RECEPTOR BLOCKADE ON ENDOTHELIAL FUNCTION: FOCUS ON OLMESARTAN MEDOXOMIL
by: C. Ferrario
Published: (2010-12-01)

Olmesartan medoxomil-loaded mixed micelles: Preparation, characterization and in-vitro evaluation
by: Mohamed A. El-Gendy, et al.
Published: (2017-12-01)

Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process
by: Mac Arturo Murillo-Fernández, et al.
Published: (2022-02-01)

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
by: Mason
Published: (2011-06-01)

ARB I olmesartan interruption in cardiovascular and cardiorenal continuum: antihypertensive and nephroprotective effects (part 1)
by: M. G Bubnova
Published: (2014-12-01)

Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice
by: Zhu Y, et al.
Published: (2019-10-01)

Blocker, angiotensin II receptor olmesartan to interrupt cardiovascular continuum: vesselsand cardioprotective, anti-atherosclerotic and metabolic pleiotropic effects (part 2)
by: M. G Bubnova
Published: (2015-03-01)

Development of Transdermal Oleogel Containing Olmesartan Medoxomil: Statistical Optimization and Pharmacological Evaluation
by: Rania Moataz El-Dahmy, et al.
Published: (2023-03-01)

Cleaning validation for residual estimation of olmesartan medoxomil on stainless steel surface of pharmaceutical manufacturing equipments using swab sampling and HPLC-DAD method
by: Nitin Dubey, et al.
Published: (2013-06-01)

Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?
by: Iwona Dams, et al.
Published: (2015-12-01)

Development and validation of stability-indicating RP-HPLC method for determination of Olmesartan medoxomile in pharmaceutical dosage form and identification, characterization of alkaline degradation impurity of Olmesartan medoxomile drug substance as well as drug product
by: Jain P.S., et al.
Published: (2012-01-01)

ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS
by: J. M. Neutel, et al.
Published: (2011-04-01)

Efficacy and safety of olmesartan medoxomil‐amlodipine besylate tablet in Chinese patients with essential hypertension: A prospective, single‐arm, multi‐center, real‐world study
by: Zhaoqiang Cui, et al.
Published: (2024-01-01)

Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines
by: Omboni S, et al.
Published: (2015-10-01)

High throughput microwell spectrophotometric assay for olmesartan medoxomil in tablets based on its charge-transfer reaction with DDQ
by: Darwish Ibrahim A., et al.
Published: (2014-03-01)

Enteropatía por olmesartán
Published: (2017-12-01)

MODERN OPPORTUNITIES FOR ANTIHYPERTENSION THERAPY: THE PLACE OF AZILSARTAN MEDOXOMIL
by: V. V. Skibitsky, et al.
Published: (2017-12-01)

Olmesartan-induced enteropathy
by: Sofia Moura de Azevedo, et al.
Published: (2023-01-01)

Novel Solid Self-Nanoemulsifying Drug Delivery System (S-SNEDDS) for Oral Delivery of Olmesartan Medoxomil: Design, Formulation, Pharmacokinetic and Bioavailability Evaluation
by: Ali Nasr, et al.
Published: (2016-06-01)

Formulation and evaluation of indomethacin biomicroparticles
by: Sudeep Gupta, et al.
Published: (2012-01-01)

ANTIHYPERTENSIVE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL AND RAMIPRIL IN ELDERLY PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION: THE ESPORT STUDY
by: E. Malacco, et al.
Published: (2012-02-01)

Olmesartan-Associated Enteropathy: An Unexpected Cause of Chronic Diarrhoea
by: Mónica Martins Teixeira, et al.
Published: (2019-04-01)

Olmesartan/amlodipine: a review of its use in the management of hypertension
by: Kreutz R
Published: (2011-03-01)

Efficacy of olmesartan amlodipine in Colombian hypertensive patients (soat study)
by: Richard Buendia, et al.
Published: (2017-04-01)

Olmesartan: A Little-Known Cause of Diarrhoea
by: Joana Serôdio, et al.
Published: (2019-06-01)

Enteropatía asociada a Olmesartan
by: Virginia González Hidalgo, et al.
Published: (2021-04-01)

Efficacy and safety of azilsartan medoxomil in various doses in patients with metabolic disorders
by: Nikita B. Perepech, et al.
Published: (2021-10-01)

Effect of Probenecid on Pharmacokinetics and Tolerability of Olmesartan in Healthy Chinese Volunteers
by: Kun-Yan Li, PhD, et al.
Published: (2014-12-01)

Combination Therapy with Olmesartan and Amlodipine in the Treatment of Hypertension
by: Menco G. Niemeijer, et al.
Published: (2009-12-01)

Synthesis of enhanced lipid solubility of indomethacin derivatives for topical formulations
by: Abualhasan Murad, et al.
Published: (2022-08-01)

Olmesartan-Induced Enteropathy: A Case of Recurrent Diarrhoea
by: Ana Rita Matos, et al.
Published: (2020-05-01)

Severe spruelike enteropathy due to olmesartan
by: Gioia Fiorucci, et al.
Published: (2014-02-01)

Olmesartan-associated Enteropathy with Acute Kidney Injury
by: Moo Jin Kang, et al.
Published: (2022-03-01)

Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension
by: Attila Juhasz, et al.
Published: (2018-02-01)

Synthesis of Some New Amides Derived from Indomethacin
by: Kawther Al-Naimi, et al.
Published: (2013-12-01)

Full spectrum and genetic algorithm-selected spectrum-based chemometric methods for simultaneous determination of azilsartan medoxomil, chlorthalidone, and azilsartan: Development, validation, and application on commercial dosage form
by: Darwish Hany W., et al.
Published: (2021-03-01)